Prospective, multicentre, randomised, double-blind, placebocontrolled, 2-parallel groups, phase 3 study to compare efficacy and safety of masitinib to placebo in the treatment of grade 2-3 non-resectable mast cell tumors in dogs not previously treated by
|Effective start/end date||3/1/16 → 2/28/17|
- AB SCIENCES
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.